MENU
DEC 03, 2020 4:30 PM PST

An Iterative Approach to Structure-based in silico to in vivo Development of Combinatorial Anti-SARS-CoV-2 Therapy

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By targeting multiple gene products simultaneously we hope to eliminate/minimize the development of treatment-resistant viral strains as was successfully done when HAART (highly active anti-retroviral therapy) was introduced for HIV-1 disease.  We employ a pipeline-based drug development process that includes multiple feedback loops between and among both in silico and laboratory-based processes for the generation of highly effective and mutation-resistant pharmaceuticals.   As part of our process to minimize the risk of the evolution of escape mutants, we begin our drug design using a suite of artificial intelligence-based machine-learning algorithms that are proven to: 1) predict future evolution (mutations) of the target viral enzymes in silico –  these sequences are added to the extant set of all protein structure files from the -coronaviruses that correspond to each of our target enzymes;  2) perform protein structure overlays of all available structures for each target enzyme to determine the most highly conserved active site morphologies; 3) prepare a 3-D grid of the conserved (consensus) active site for each target enzyme;  4) using a 3-step in silico funnel process, with increased-stringency at each step, run each consensus target active-site against multiple large druggable compound libraries, including all FDA-approved drugs, to obtain ‘hit’ compounds.  These ‘hit’ compounds are then simultaneously moved into: a) our in silico molecular dynamics pipeline to identify and characterize the active-site interacting groups (molecular domains) which will be used as one of the inputs into our structure-activity relationship (SAR) modeling to rationally build derivative compounds with greater affinities; and b) our three-phase laboratory biophysical-biochemical pipeline consisting of (i) surface plasmon resonance for protein binding kinetics, (ii) functional enzyme inhibition studies, and (iii) isothermal titration calorimetry and microscale thermophoresis to obtain precise stoichiometry and binding affinities under multiple liquid-phase parameters.  Hit compounds meeting both preset biophysical and biochemical criteria will be moved as “leads” into the antiviral testing arm of the pipeline.  Those compounds showing promise, but without high enough binding scores or IC50 values will be moved in the SAR pipeline for the development of rationally-designed derivatives.  Results from the SAR studies will be screened for their ease/predicted yields of synthesis, and then process-specific software will be used to augment protocols for their organic syntheses.  Lead compounds will be evaluated individually, and as cocktails of two and three compounds targeting different enzymes, for: 1) human cell toxicity; 2) SARS-CoV-2 virological studies using Calu-3 cells and human airway epithelial cells; and 3) in a physiologically relevant lung-on-a-chip system. Emergence of viral escape mutants in response to lead compounds will be sequenced and inform the synthesis of escape-resistant antiviral drugs. Finally, the prophylactic/therapeutic in vivo antiviral efficacy of lead compounds will be determined in animal models of coronavirus infection and pathogenesis.

Learning Objectives:

1. Learn applications of deep-learning algorithms and machine-learning techniques to help with the design of escape-resistant drugs for infectious agents

2. Learn targeting strategies to minimize the evolution of escape mutants


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
JUL 15, 2021 9:00 AM PDT
JUL 15, 2021 9:00 AM PDT
Date: July 15, 2021 Time: 9:00am (PDT), 12:00pm (EDT) The Pisces workflow robust, easy-to-use, end-to-end multi-omics solution for highly multiplexed targeted Spatial RNA analysis. VeranomeB...
DEC 03, 2020 4:30 PM PST

An Iterative Approach to Structure-based in silico to in vivo Development of Combinatorial Anti-SARS-CoV-2 Therapy

C.E. Credits: P.A.C.E. CE Florida CE

No demographic data is available yet for this event.


Show Resources
Loading Comments...
Show Resources